A Large Pooled Safety Analysis of 3 Post-Marketing Studies Conducted in Inflammatory Bowel Disease Patients Treated with Biosimilar Infliximab (CT-P13)

Sang Joon Lee  1     KyungMin Baek  1     Yoon Jee Lee  1     Sujin Lee  1     Houng Kim  2     Seul Gi Lee  1     Jeong Eun Park  1    
1 Celltrion,Incheon,Korea (Republic of)
2 Celltrion Healthcare,Incheon,Korea (Republic of)

IBD I (Posters)

UEG Week 2019

United European Gastroenterology Journal Volume 7 Issue 8 (Supplement), October 2019

Login to access library content


Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Forgot your password?

Reset myUEG password

Social Sharing